News

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which is claimed to be the only FDA-approved product to treat adults with TD. FDA approval was based

Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications. NuBiyota will receive an upfront payment and is

The platform will enable BioCelerate's member companies to aggregate and analyze preclinical and clinical information to improve drug development efficiency and bring new medicines to patients faster. Kevin Julian,

The global and randomised phase III ALEX study met its primary endpoint, demonstrating that Alecensa as an initial (first-line) treatment has decreased the risk of disease worsening or death

The models will predict therapeutic indications and side effects from several drug information sources The invention of the new machine learning models is likely to pave way for

The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive either 0.5% remetinostat gel BID, 1% remetinostat gel QD or

Harvoni was approved for pediatric patients with genotype 1, 4, 5 or 6 chronic HCV infection. Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic

The company intends to provide data from trial evaluating cardiovascular outcomes with sitagliptin (TECOS), which includes prescribing information of sitagliptin-containing medicines. The TECOS trial, which involved 4,724 patients

Under the terms of the license agreement, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases.